TJ DaRenTang USD News

Tianjin Pharmaceutical Group Finance to Raise Capital to 1 Billion Yuan

MT NewswiresSep 8 23:08 ET

Tianjin Pharmaceutical's Attributable Profit Down 16% in Q2

MT NewswiresAug 14 22:19 ET

Tianjin Pharmaceutical Da Ren Tang Confirms Business Validity of Controlling Shareholder's Finance Unit

MT NewswiresAug 14 22:11 ET

TJ DaRenTang USD: Financial Statements and Related Announcement-Second Quarter and/ or Half Yearly Results

SGXAug 14 05:56 ET · Announcements

Tianjin Pharmaceutical Da Ren Tang Repays 350 Million Yuan Temporary Use Funds

MT NewswiresAug 11 22:20 ET

Tianjin Pharma Ups Stake in Tianjin Pharmaceutical Group Finance to 30%

MT NewswiresAug 6 01:09 ET

TJ DaRenTang USD To Go Ex-Dividend On July 2nd, 2024 With 0.1761 USD Dividend Per Share

Moomoo NewsJun 25 17:20 ET

TJ DaRenTang USD: Annual Reports and Related Documents

SGXMay 28 05:06 ET · Announcements

Tianjin Pharmaceutical's Q1 Attributable Profit Slips 3%

MT NewswiresApr 30 01:01 ET

Daren Tang (600329.SH) announced its 2023 annual results, with net profit of 987 million yuan, an increase of 14.49% over the previous year. It plans to distribute 10 to 12.8 yuan

According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders. In 2023, the company will firmly implement “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural goods

Zhitong FinanceMar 29 06:36 ET

Singapore-listed Manufacturers Book Mixed Returns in Early 2024

Singapore ExchangeFeb 19 04:21 ET

Portion of Tianjin Pharmaceutical Controlling Shareholder's Shares Placed Under Judicial Freeze

MT NewswiresJan 9 18:23 ET

Tianjin Pharmaceutical Taps Affiliate for Brand Promotion

MT NewswiresDec 20, 2023 03:24 ET

Tianjin Pharmaceutical Hires Contractor for Renovation of Workshop, Warehouses

MT NewswiresDec 19, 2023 23:38 ET

Da Ren Tang (600329.SH): Intends to sign a contract with Tianjin Pharmaceutical Design Institute Co., Ltd.

Gelonghui (600329.SH) announced on December 19丨Da Rentang () announced that in order to integrate the medicinal herbs and tablet business lines and achieve integrated management of tablets and related businesses, the company plans to build a new tablet production workshop, decoction center and supporting facilities in the existing Qingguang South Reservoir area, and upgrade warehouses in the northern storage area. Based on this plan, the company plans to carry out the “Jinyao Da Rentang Drink Factory Relocation and Renovation Project - Frying Workshop Single Project” and the “Jinyao Da Rentang Pharmaceutical Company Qingguang Reservoir North Reservoir Area Renovation Project - 27 #29 #43 #库改造工程” project. According to the bidding results, Tianjin Pharmaceutical Design Institute Co., Ltd.

Gelonghui FinanceDec 19, 2023 04:16 ET

Da Ren Tang (600329.SH): Some products note the lifting of restrictions and adjustments and changes in the “National Health Insurance Catalogue”

<国家基本医疗保险、工伤保险和生育保险药品目录（2023年）>Gelonghui, December 15|Da Rentang (600329.SH) announced that the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance”. In the “2023 Medical Insurance Catalogue”, the comment restrictions on some products of Jinyao Da Rentang Group Co., Ltd. have been lifted or adjusted. The content of the comment restrictions on the company's related products has been partially adjusted, and some restrictions have been lifted, which is expected to have a positive effect on the future promotion and application of the company's related products. More patients will benefit from the adjustment of health insurance restrictions

Gelonghui FinanceDec 15, 2023 02:39 ET

Da Ren Tang (600329.SH): The shareholding structure of the controlling shareholder has changed

Gelonghui (600329.SH) announced on November 22|Da Rentang () announced that it recently received the “Notice Letter on Changes in the Shareholding Structure of Pharmaceutical Group” from the controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., which adjusted the original pharmaceutical group equity transfer plan according to the overall deployment and strategic planning arrangements of the superior units of the pharmaceutical group's shareholders. The equity structure of the Pharmaceutical Group has changed, and the registration of industrial and commercial changes in equity matters has been completed. Tianjin Bohai Guoxin Technology Co., Ltd., a shareholder of Pharmaceutical Group, used its 33% stake in Pharmaceutical Group to increase capital to its wholly-owned subsidiary Tianjin Guoyu Enterprise Management Co., Ltd.

Gelonghui FinanceNov 22, 2023 04:32 ET

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Simply Wall StNov 18, 2023 19:24 ET

Private Companies Own 43% of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Shares but Retail Investors Control 46% of the Company

Yahoo FinanceNov 12, 2023 21:57 ET

Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Using Too Much Debt?

Simply Wall StNov 2, 2023 22:15 ET